Hereditary Cancer in Clinical Practice This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Prognostic factors in Polish patients with BRCA1 -dependent ovarian cancer
Conclusion Prognostic factors for favourable treatment outcomes in Polish patients with BRCA1-OC do not appear to differ from those in patients with sporadic OC. The incidence of the endometrial subtype of OC was relatively high (34.9 %) among women in the study. This was unexpected and has not been reported previously. This subtype of OC was an independent prognostic factor for favourable treatment outcomes. (Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - January 23, 2016 Category: Cancer & Oncology Source Type: research

BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population
Conclusion The current study indicates that founder BRCA1 mutations reported in Polish breast/ovarian cancer patients do not contribute to increased GC risk. The nine tested recurrent BRCA1 and BRCA2 mutations were not detected in GC patients which may suggests that they are rare in GC patients in the Polish population. Further analyses, including sequencing of entire sequences of BRCA1 and BRCA2 genes, are necessary to ultimately determine the role of these two genes in GC in Poland. (Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - January 15, 2016 Category: Cancer & Oncology Source Type: research

Association of polymorphisms with a family history of cancer and the presence of germline mutations in the BRCA1/BRCA2 genes
Conclusion The results presented here provide interesting data on the modifying effect of polymorphisms on a family history of cancer; this may be a variable to consider in the analysis of tumor diversity, and of the family history observed in families with hereditary breast cancer (even in those harboring the same type of genetic alteration). (Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - January 13, 2016 Category: Cancer & Oncology Source Type: research

Clinical features and outcomes of germline mutation BRCA1 -linked versus sporadic ovarian cancer patients
Conclusion In conclusion, we found better overall survival for ovarian cancer patients with BRCA1 germline mutations in comparison with patients without these mutations (sporadic) ovarian cancer. Thus, BRCA1 germline mutations appear to be an independent prognostic factor for ovarian cancer. (Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - January 8, 2016 Category: Cancer & Oncology Source Type: research

Magnesium as a diagnostic marker of cancer
(Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - November 26, 2015 Category: Cancer & Oncology Source Type: research

Zinc as diagnostic marker of cancers
(Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - November 26, 2015 Category: Cancer & Oncology Source Type: research

Factors influencing effective acquisition of primary care patients for cancer early diagnostics
(Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - November 26, 2015 Category: Cancer & Oncology Source Type: research

The role of selected egzo- and endogenic agents on preinitiation process of bladder cancer
(Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - November 26, 2015 Category: Cancer & Oncology Source Type: research

RET gene mutations spectrum in patients with medullary thyroid carcinoma (MTC) from Great Poland region
(Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - November 26, 2015 Category: Cancer & Oncology Source Type: research

Copper transport system and response to ovarian cancer chemotherapy
(Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - November 26, 2015 Category: Cancer & Oncology Source Type: research

Pharmacogenetics of FAC chemotherapy side effects in breast cancer patients
(Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - November 26, 2015 Category: Cancer & Oncology Source Type: research

Copper as diagnostic marker of cancers
(Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - November 26, 2015 Category: Cancer & Oncology Source Type: research

Iron as diagnostic marker of cancer
(Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - November 26, 2015 Category: Cancer & Oncology Source Type: research

Selenium as diagnostic marker of cancers
(Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - November 26, 2015 Category: Cancer & Oncology Source Type: research

Micronutrient supplementation for cancer prevention
(Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - November 26, 2015 Category: Cancer & Oncology Source Type: research